Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.
OBJECTIVE
To evaluate the importance and potential of Cyfra21-1 as a tumor marker (TM) for follow-up of patients with squamous cell carcinoma (SCC) in laryngeal and hypopharyngeal cancer.


METHODS
Cyfra21-1 serum levels of 50 patients with laryngeal and hypopharyngeal SCC were evaluated by ECLIA assay. Statistical analysis was performed using Kruskal-Wallis and Jonckheere-Terpstra tests.


RESULTS
There was no significant correlation between Cyfra21-1 levels at the time of initial diagnosis and the clinicopathological parameters. The clinical performance of Cyfra 21-1 as an individual tumor marker for follow-up of patients was good. This is shown by the area under the curve (0.873) of their receiver operating characteristic curves. The sensitivity and specificity of Cyfra 21-1 at a cut-off 3.3 ng/ml ere 61.1% and 96.9% respectively.


CONCLUSIONS
Cyfra 21-1 is not suitable for early diagnosis of SCC of the larynx and hypopharynx. An abrupt increase of Cyfra 21-1 in serial measurements indicates impending disease progression in individual patients.
Al-Shagahin
Hani
H
Department of Otolaryngology, Head and Neck Surgery, Philipps University of Marburg, D-35037 Marburg, Germany.
Alkotyfan
Khaled
K
Müller
Hans-Helge
HH
Sesterhenn
Andreas M
AM
Werner
Jochen A
JA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000175:diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000097:blood* / Q000175:diagnosis; D053539:Keratin-19 / Q000097:blood*; D007822:Laryngeal Neoplasms / Q000097:blood* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D012680:Sensitivity and Specificity
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; C102012:antigen CYFRA21.1